Five years follow-up study and failures analysis of Botulinum toxin repeated injections to treat neurogenic detrusor overactivity

Gaillet, S.; Bardot, Philippe; Bernuz, B.; Boissier, R.; Lenne-Aurier, K.; Thiry-Escudier, I; Tournebise, H.; Lechevallier, É.; Karsenty, G.

doi:10.1016/j.purol.2012.10.006

Cited by 19 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The causes of primary or secondary failure of BTA IDI remain poorly understood. Regarding primary failure, poorer outcomes of IDI in patients with low compliance bladder have been suggested . The assumptions usually made to explain secondary failure are the development of neutralizing antibodies to botulinum toxin and the occurrence of bladder wall fibrosis after repeated injections decreasing the spread of BTA in the detrusor .…”

Section: Discussionmentioning

confidence: 99%

“…Regarding primary failure, poorer outcomes of IDI in patients with low compliance bladder have been suggested . The assumptions usually made to explain secondary failure are the development of neutralizing antibodies to botulinum toxin and the occurrence of bladder wall fibrosis after repeated injections decreasing the spread of BTA in the detrusor . The immunological hypothesis has been challenged during the past few years due to the discrepancy observed between the presence of antibodies and non‐response to the toxin (presence of anti‐toxin antibodies in 40% of responders and absence in 50% of non‐responders .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed

Bottet

Peyronnet

Boissier

et al. 2017

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aims: To assess the outcomes of switching to a different brand of botulinum toxin A (BTA, from Botox® to Dysport®) in case of failure of intradetrusor injections (IDI) of Botox® in the treatment of neurogenic detrusor overactivity (NDO). Methods: The charts of all patients who underwent a switch to IDI of Dysport® after failure of an IDI of Botox® at six departments of neurourology were retrospectively reviewed. The main outcomes of interest were the bladder diary data and four urodynamic parameters: maximum cystometric capacity (MCC), maximum detrusor pressure (PDET max), and volume at first uninhibited detrusor contraction (UDC). Results: Fifty-seven patients were included. After the first injection of Dysport®, no adverse events were reported. A significant decrease in number of urinary incontinence episodes per day was observed in 52.63% of patients (P < 0.001) and all patients experienced a reduction in PDET Max (−8.1 cmH20 on average; P = 0.003). MCC significantly increased by a mean of 41.2 (P = 0.02). The proportion of patients with no UDC increased significantly at week 6 after ATA injections (from 15.79% to 43.9%; P = 0.0002). Hence, 32 patients draw clinical and/or urodynamic benefits from the botulinum toxin switch from (56.14%). After a median follow up of 21 months, 87% of responders to BTA switch were still treated successfully with BTA.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed

Bottet

Peyronnet

Boissier

et al. 2017

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…[11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] The level of evidence of the included studies ranged from 3 to 4. Ten studies were retrospective case series, [12][13][14][15][16][17][18][19]22,27 seven studies were prospective cohort studies 11,20,21,23,24,26,28 and the remaining article was a mixed study comprising both retrospective and prospective components. 25 Thirteen studies used Botox, 12,15,[17][18][19][20][21][23][24][25][26][27][28] four studies used Dysport, …”

Section: Study and Patient Characteristicsmentioning

confidence: 99%

“…Ten studies were retrospective case series, [12][13][14][15][16][17][18][19]22,27 seven studies were prospective cohort studies 11,20,21,23,24,26,28 and the remaining article was a mixed study comprising both retrospective and prospective components. 25 Thirteen studies used Botox, 12,15,[17][18][19][20][21][23][24][25][26][27][28] four studies used Dysport, 13,14,16,22 and one study used both Botox and Dysport. 11 Botox was administered at doses of 200 or 300 U, and Dysport was administered at doses ranging from 500 to 1000 U.…”

Section: Study and Patient Characteristicsmentioning

confidence: 99%

Is repeat Botulinum Toxin A injection valuable for neurogenic detrusor overactivity—A systematic review and meta‐analysis

Wang

Cao

et al. 2017

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…94 An increase in the difficulty of CIC and progression of disability often resulted in the discontinuation of repeated injections of this high dose of BoNTA among patients with mul tiple sclerosis. 95 Thus, a smaller dose of BoNTA, such as 100 units, was used in the treatment of patients with multiple sclero sis who wished to improve their OAB symptoms but also wished to urinate voluntarily after treatment. In one study, patients with multiple sclerosis had improvements in all urodynamic and voiding diary variables after i njection of 100 units of BoNTA.…”

Section: Ndo Owing To Neuropathiesmentioning

confidence: 99%

Current and potential urological applications of botulinum toxin A

Jiang

Liao

2015

Nat Rev Urol

View full text Add to dashboard Cite

Botulinum toxin subtype A (BoNT-A) is a potent neurotoxin that can selectively modulate neurotransmitter release from nerve endings, resulting in muscular paralysis. BoNT-A might also act on sensory nerves, and have an anti-inflammatory effect. In the first urological use of BoNT-A, injection into the urethral sphincters of patients with detrusor-sphincter dyssynergia resulted in a reduction of urethral resistance and improved voiding efficiency. Subsequently, intravesical BoNT-A injections have received regulatory approval for treatment of neurogenic detrusor overactivity owing to spinal cord lesions or multiple sclerosis, and idiopathic overactive bladder in adults. BoNT-A has also been widely used to treat patients with the off-label indications of neurogenic or non-neurogenic voiding dysfunction and male lower urinary tract symptoms owing to BPH and bladder-neck dysfunction. Other indications for which urologists have applied BoNT-A injections include interstitial cystitis/bladder pain syndrome, bladder oversensitivity and chronic pelvic pain syndrome. BoNT-A is currently delivered as an intravesical injection; however, use of liposome encapsulated formulations is also beginning to show some therapeutic potential.

show abstract

Five years follow-up study and failures analysis of Botulinum toxin repeated injections to treat neurogenic detrusor overactivity

Cited by 19 publications

References 30 publications

Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed

Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed

Is repeat Botulinum Toxin A injection valuable for neurogenic detrusor overactivity—A systematic review and meta‐analysis

Current and potential urological applications of botulinum toxin A

Contact Info

Product

Resources

About